Navigation Links
Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
Date:10/28/2009

BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. 28 /PRNewswire/ -- Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch ("HES") which will be combined with a recombinant protein from Octapharma's human cell-line platform -- this combination is intended to generate a therapeutic protein with a superior product profile.

Fresenius Kabi will seek to adapt and optimize the protein modification by its HESylation® Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma. Under the agreement, Octapharma will oversee the further development and commercialization. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation® Technology.

Octapharma's human cell-line platform

Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell lines. Over the last twelve years, Octapharma has successfully established the human HEK293F cell-line platform for the expression of a variety of recombinant therapeutic proteins on a commercial scale.

An investigational new drug application for Octapharma's human cell-line derived recombinant FVIII was filed in the U.S. in May 2008. Using a human cell-line expression system instead of e.g. hamster cell-lines is expected to result in possible advantages like improved protein functions, increased tolerability and the opportunity for reduced immunogenicity.

HESylation® Technology

HESylation® Technology is based on the extensive expertise in the field of hydroxyethyl starch ("HES") that Fresenius Kabi has gathered as the world's largest producer of pharmaceutical grade HES. HES is derived from waxy maize starch and can be metabolized by the body's enzymes. HES solutions have been safely administered for over 30 years to treat deficient blood volume and to improve the rheological properties of blood.

HESylation® Technology allows a targeted modification of drugs and their characteristics by a site-specific coupling to HES molecules. This can modify key pharmacological parameters such as absorption, metabolization, half-life, water solubility and safety.

HESylation® Technology is covered by a broad portfolio of intellectual property rights. For further details please visit http://www.HESylation.com.

About Octapharma Group

The Octapharma Group is an independent, Swiss-based biopharmaceutical company operating worldwide. Octapharma's core business is the development, production, and sale of high-quality human proteins for the treatment of life-threatening diseases.

The Group has more than 3,500 employees in 28 countries, and owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden, and Mexico, respectively. Sales turnover in 2008 reached Euro 886 million with an EBIT of Euro 256 million.

For more information about Octapharma Group please visit the company's website: www.octapharma.com

Fresenius Kabi

Fresenius Kabi is focused on products for the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume substitution and intravenously administered drugs as well as parenteral and enteral nutrition and the medical devices for the application.

Fresenius Kabi has more than 20,000 employees worldwide and a global network of around 55 sales organizations and more than 55 production sites. In 2008, Fresenius Kabi achieved sales of Euro 2,495 million and an operating profit (EBIT) of Euro 443 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.

For more information about Fresenius Kabi, please visit the company's web site at www.fresenius-kabi.com.

SOURCE Octapharma


'/>"/>
SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
5. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
6. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
7. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
8. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
9. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
10. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
11. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):